Back to discover
Drug

Vinblastine

In clinical development
Emerging researchLate-stage developmentRising momentum
Also known as VLB, Vincaleukoblastine, Vinblastin, Vinblastina+2 more

VLB, Vincaleukoblastine, Vinblastin, Vinblastina, VinBLAStine Sulfate, Vinblastinum.

RxNorm11198ChEMBLCHEMBL159ATCL01CA01UNII5V9KLZ54CY
3
Research papers
31
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation in Advanced Hodgkin Lymphoma

Clinical trial2026-07-09Results expected Q1 2032 · ClinicalTrials.gov

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Clinical trial2026-07-09Results expected Q2 2031 · ClinicalTrials.gov

A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

Clinical trial2026-07-08Results expected Q3 2027 · ClinicalTrials.gov

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

Clinical trial2026-07-08Results expected Q3 2030 · ClinicalTrials.gov

A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Clinical trial2026-07-02Results expected Q4 2026 · ClinicalTrials.gov

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Clinical trial2026-07-02Results posted · ClinicalTrials.gov

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Clinical trial2026-06-17Results expected Q1 2027 · ClinicalTrials.gov

A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Clinical trial2026-06-11Results expected Q4 2028 · ClinicalTrials.gov

Estimating the global burden of Epstein-Barr virus-related cancers.

Research2021-10-27Journal of cancer research and clinical oncology

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Research2017-02-17The New England journal of medicine

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Research2003-08-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Vinblastine
Aliases & brands
VLBVincaleukoblastineVinblastinVinblastinaVinBLAStine SulfateVinblastinum
RxNorm CUI
11198
ChEMBL ID
CHEMBL159
ATC codes
L01CA01
UNII
5V9KLZ54CY

Clinical trials

144 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
144
registered trials across all phases
LATEST COMPLETION 2026
31
Active studies
14
Recruiting
57
Late-stage (III+)
78
Completed
35
Discontinued
PHASE DISTRIBUTIONn = 144
Early Phase 12Phase 19Phase 1 / 27Phase 269Phase 2 / 33Phase 346Phase 43Phase N / A5

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine in Indian Patients With Untreated Stage 3/4 Classical Hodgkin Lymphoma

RecruitingPH IVTakedan=1242028

First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents

CompletedPH IVChristine Mauz-Körholzn=2252023

Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

CompletedPH IVBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladeshn=602018

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

RecruitingPH IIIKey trialUniversity College, Londonn=1,0422032

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

RecruitingPH IIIKey trialNational Cancer Institute (NCI)n=1,8752031

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

CompletedN/AMemorial Sloan Kettering Cancer Centern=1182026

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

CompletedPH IIIKey trialTakedan=1,3342026

A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)

CompletedPH IIFox Chase Cancer Centern=782025

Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invasive Bladder Cancer: A Pilot Trial

CompletedPH IIUniversity of Washingtonn=172025

A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL).

CompletedPH IIIFondazione Italiana Linfomi - ETSn=5002024

Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)

CompletedPH IIMerck Sharp & Dohme LLCn=1462024

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20032022
Most influential

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

The New England journal of medicine · 2017 · 2,620 cites

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

The New England journal of medicine · 2003 · 1,909 cites

Estimating the global burden of Epstein-Barr virus-related cancers.

Journal of cancer research and clinical oncology · 2022 · 216 cites
Recent papers

Estimating the global burden of Epstein-Barr virus-related cancers.

Journal of cancer research and clinical oncology · 2022 · 216 cites

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

The New England journal of medicine · 2017 · 2,620 cites

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

The New England journal of medicine · 2003 · 1,909 cites
Major research themes1
Cystectomy1
Journals, researchers & institutions
Top journals
  • The New England journal of medicine2
  • Journal of cancer research and clinical oncology1
Leading researchers
  • Vogelzang NJ2
  • Bajorin DF1
  • Bellmunt J1
  • Burrows SR1
  • Choueiri TK1
  • Climent MA1
  • Crawford ED1
  • Culine S1
Leading institutions
free-text, unnormalised
  • Australian Institute of Tropical Health and Medicine1
  • Centre for Molecular Therapeutics1
  • Centre for Tropical Bioinformatics and Molecular Biology1
  • From Dana-Farber Cancer Institute1
  • M.D. Anderson Cancer Center1
  • QIMR Berghofer Medical Research Institute1

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Doxorubicin

Studied across 12 of the same disease areas as Vinblastine in the shared literature.

12 shared diseases2 shared papers
Bleomycin

Studied across 9 of the same disease areas as Vinblastine in the shared literature.

9 shared diseases1 shared paper
Dacarbazine

Studied across 9 of the same disease areas as Vinblastine in the shared literature.

9 shared diseases1 shared paper
Cisplatin

Studied across 7 of the same disease areas as Vinblastine in the shared literature.

7 shared diseases1 shared paper
Pembrolizumab

Studied across 6 of the same disease areas as Vinblastine in the shared literature.

6 shared diseases1 shared paper
Docetaxel

Studied across 5 of the same disease areas as Vinblastine in the shared literature.

5 shared diseases1 shared paper
Paclitaxel

Studied across 4 of the same disease areas as Vinblastine in the shared literature.

4 shared diseases1 shared paper
Methotrexate

Studied across 3 of the same disease areas as Vinblastine in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials